文献速递炎症性肠病胃肠动力与功能性疾病

复发性艰难梭菌感染及粪菌移植后的长期结局

Long-term Outcomes Following Multiply Recurrent Clostridioides difficile Infection and Fecal Microbiota Transplantation.
PubMed 文献 · Clin Gastroenterol Hepatol · 2020-12-08

本研究基于美国商业保险数据库的回顾性队列,评估复发性艰难梭菌感染(mrCDI)及粪菌移植(FMT)与心脏代谢、免疫介导疾病及肠易激综合征的关联。结果显示mrCDI本身不增加上述疾病风险,但接受FMT者心肌梗死发生率升高(aHR=1.68;95%CI 1.01-2.81)。

要点

  • mrCDI与非mrCDI相比,IBD、类风湿关节炎、银屑病、糖尿病、高血压、心梗、卒中及IBS风险均无显著差异。
  • FMT vs 未接受FMT的mrCDI,糖尿病、高血压、卒中及IBS风险无显著差异。
  • 接受FMT者心肌梗死发生率升高(aHR=1.68;95%CI 1.01-2.81),需未来研究验证。

核心结论

  • 相对CDI患者,mrCDI患者本身不增加心脏代谢、免疫介导疾病或IBS风险。
  • 因CDI接受FMT者心肌梗死发生率升高,需未来研究评估可重复性。

研究设计与样本

  • 基于美国商业保险索赔数据库的回顾性队列研究,纳入诊断为CDI或接受FMT的个体。
  • 设置两组配对比较:mrCDI vs 非mrCDI;非mrCDI或mrCDI接受FMT vs mrCDI未接受FMT。

主要发现

  • mrCDI vs 非mrCDI:IBD aHR=1.65(95%CI 0.67-4.04);类风湿关节炎HR=0.86(0.47-1.56);银屑病HR=0.72(0.23-2.27);糖尿病aHR=0.97(0.67-1.40);高血压aHR=1.05(0.76-1.44);心肌梗死aHR=0.82(0.63-1.06);卒中aHR=0.83(0.62-1.12);IBS HR=0.94(0.61-1.45)。
  • CDI接受FMT vs mrCDI未接受FMT:糖尿病aHR=0.92(0.27-3.11);高血压aHR=1.41(0.64-3.15);卒中aHR=1.27(0.69-2.34);IBS aHR=0.80(0.26-2.46)。
  • CDI接受FMT vs mrCDI未接受FMT:心肌梗死发生率升高,aHR=1.68(95%CI 1.01-2.81)。

临床怎么用

  • 对mrCDI患者,无需因担心心脏代谢、免疫介导疾病或IBS风险而改变管理策略。
  • 对接受FMT的CDI患者,应关注心肌梗死风险,尤其在高危人群中加强监测。

局限性

  • 回顾性队列设计可能受残余混杂影响。
  • 基于商业保险索赔数据库,可能存在编码偏倚和未测量混杂。
  • 心肌梗死风险升高为观察性关联,需未来研究验证可重复性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Fecal microbiota transplantation (FMT) is a commonly used therapy for multiply recurrent Clostridioides difficile (mrCDI). By altering the gut microbiota, there is the potential for FMT to impact the risk for cardiometabolic, intestinal or immune-mediated conditions. Likewise, the microbiota disturbance associated with mrCDI could potentially lead to these conditions. We aimed to assess the associations of mrCDI and FMT with cardiometabolic, immune-mediated diseases, and irritable bowel syndrome. METHODS: This retrospective cohort study using a United States commercial claims database included persons diagnosed with CDI or undergoing FMT. We created 2 pairwise comparisons: mrCDI vs non-mrCDI, and non-mrCDI or mrCDI treated with FMT vs mrCDI without FMT. RESULTS: We found no significant association between mrCDI (vs non-mrCDI) and inflammatory bowel disease (adjusted hazard ratio (aHR) = 1.65; 95% confidence interval, 0.67-4.04), rheumatoid arthritis (HR = 0.86; 0.47-1.56), psoriasis (HR = 0.72; 0.23-2.27), diabetes (aHR = 0.97; 0.67-1.40), hypertension (aHR = 1.05; 0.76-1.44), myocardial infarction (aHR = 0.82; 0.63-1.06), stroke (aHR = 0.83; 0.62-1.12), or irritable bowel syndrome (HR = 0.94; 0.61-1.45). Similarly, we found no association of CDI with FMT (vs mrCDI without FMT) and diabetes (aHR = 0.92; 0.27-3.11), hypertension (aHR = 1.41; 0.64-3.15), stroke (aHR = 1.27; 0.69-2.34) or inflammatory bowel syndrome (aHR = 0.80; 0.26-2.46). However, the incidence of myocardial infarction was increased following FMT (aHR = 1.68; 1.01-2.81). CONCLUSION: Relative to those with CDI, persons with mrCDI do not appear to be intrinsically at higher risk of cardiometabolic, immune-mediated diseases, or irritable bowel syndrome. However, those who underwent FMT for CDI had a higher incidence of myocardial infarction. Future studies should assess this association to assess reproducibility.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Dawwas GK, Brensinger CM, Vajravelu RK, et al. Long-term Outcomes Following Multiply Recurrent Clostridioides difficile Infection and Fecal Microbiota Transplantation. Clin Gastroenterol Hepatol. 2020. PMID: 33307184. doi:10.1016/j.cgh.2020.12.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。